Epidemiology of a mumps outbreak in a highly vaccinated island population and use of a third dose of measles-mumps-rubella vaccine for outbreak control - Guam 2009 to 2010

Pediatric Infectious Disease Journal

Volumn 32, Issue 4, 2013, Pages 374-380

  Nelson, George E ^a,b   Aguon, Annette ^c   Valencia, Engracia ^c   Oliva, Rita ^c   Guerrero, Michele Leon ^c   Reyes, Richard ^c   Lizama, Anna ^c   Diras, Daryl ^c   Mathew, Annakutty ^c,d   Monforte, Moryne Nicole ^e   Chen, Tai Ho ^e   Mahamud, Abdirahman ^b   Kutty, Preeta K ^a,b   Hickman, Carole ^a   Bellini, William J ^a   Seward, Jane E ^a   Gallagher, Kathleen ^b   Fiebelkorn, Amy Parker ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c Guam Department of Public Health and Social Services   (Guam)

^d Guam Memorial Hospital   (Guam)

^e Guam Department of Education   (Guam)

Author keywords

Immunization; Mumps; Outbreak control; Third dose measles mumps rubella intervention; Vaccine preventable disease

Indexed keywords

MEASLES MUMPS RUBELLA VACCINE;

ADOLESCENT; ADULT; AGED; ARTHRALGIA; ARTICLE; CHILD; CROWDING; DISEASE SURVEILLANCE; DIZZINESS; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; INCUBATION TIME; INFANT; INJECTION SITE PAIN; INJECTION SITE SWELLING; MAJOR CLINICAL STUDY; MALE; MUMPS; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK FACTOR; SCHOOL CHILD; VACCINATION REACTION;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; CROWDING; DISEASE OUTBREAKS; ETHNIC GROUPS; FEMALE; GUAM; HUMANS; INFANT; MALE; MEASLES-MUMPS-RUBELLA VACCINE; MIDDLE AGED; MUMPS; SOCIOECONOMIC FACTORS; YOUNG ADULT;

EID: 84876296365     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e318279f593     Document Type: Article

References (43)

1. Plotkin SA, Rubin SA. Mumps vaccine. In: Plotkin S, Orenstein W, Offit P, eds. Vaccines. 5th ed. Philadelphia: Saunders; 2008;435-465.
2. Philip RN, Reinhard KR, Lackman DB. Observations on a mumps epidemic in a virgin population. Am J Hyg. 1959;69:91-111.
3. Falk WA, Buchan K, Dow M, et al. The epidemiology of mumps in southern Alberta 1980-1982. Am J Epidemiol. 1989;130:736-749.
4. Koskiniemi M, Donner M, Pettay O. Clinical appearance and outcome in mumps encephalitis in children. Acta Paediatr Scand. 1983;72:603-609.
5. Everberg G. Deafness following mumps. Acta Otolaryngol. 1957;48:397-403.
6. Tarkkanen J, Aho J. Unilateral deafness in children. Acta Otolaryngol. 1966;61:270-278.
7. Werner CA. Mumps orchitis and testicular atrophy; occurrence. Ann Intern Med. 1950;32:1066-1074.
8. Centers for Disease Control and Prevention. Mumps vaccine. MMWR. Morb Mortal Wkly Rep. 1977;26:393-394.
9. Centers for Disease Control and Prevention. Measles prevention. MMWR Morb Mortal Wkly Rep. 1989;38(suppl 9):1-18.
10. Barskey AE, Glasser JW, LeBaron CW. Mumps resurgences in the United States: A historical perspective on unexpected elements. Vaccine. 2009;27:6186-6195.
11. US Department of Health and Human Services (HHS). Healthy People 2010: Understanding and Improving Health. Washington, DC: US Government Printing Office (GPO); 2000.
12. Dayan GH, Quinlisk MP, Parker AA, et al. Recent resurgence of mumps in the United States. N Engl J Med. 2008;358:1580-1589.
13. Barskey AE, Schulte C, Rosen JB, et al. Mumps outbreak in Orthodox Jewish communities in the United States. N Engl J Med. 2012;367:1704-1713.
14. Ogbuanu IU, Kutty PK, Hudson JM, et al. Impact of a third dose of measles-mumps-rubella vaccine on a mumps outbreak. Pediatrics. 2012;130: e1567-1574.
15. Bureau of Statistics and Plans Office of Governor. 2008 Guam Statistical Yearbook. Hagatna, Guam 2009. Available at: http://www.bsp.guam.gov/2008- Guam%20Statistical%20Yearbook.pdf. Accessed December. 10, 2012.
16. CDC. Measles, mumps, and rubella-vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 1998;47(RR-8):1-57.
17. Council of State and Territorial Epidemiologists. Position statement 09-ID-50, revision of the surveillance case definition for mumps. 2008. Available at: http://www.cste.org/ps2009/09-ID-50.pdf Accessed December 7, 2012.
18. Centers for Disease Control and Prevention. Real-time (TaqMan®) RT-PCR assay for the detection of mumps virus RNA in clinical samples. 2010 [cited July 24, 2012]. Available at: http://www.cdc.gov/mumps/downloads/lab-rt- pcr-assay-detect.doc. Accessed December 10, 2012.
19. Rota JS, Turner JC, Yost-Daljev MK, et al. Investigation of a mumps outbreak among university students with two measles-mumps-rubella (MMR) vaccinations, Virginia, September-December 2006. J Med Virol. 2009;81:1819-1825.
20. Jin L, Rima B, Brown D, et al. Proposal for genetic characterisation of wild-type mumps strains: preliminary standardisation of the nomenclature. Arch Virol. 2005;150:1903-1909.
21. American Academy of Pediatrics. Mumps. In: Pickering LK, Baker CJ, Kimberlin DW, Long SS, eds. Red Book: 2009 Report of the Committee on Infectious Diseases. Elk Grove Village, IL: American Academy of Pediatrics; 2009:468-472.
22. CDC. Vaccine adverse event reporting system (VÂERS). 2012 [updated June 5,2012]. Available at: http://www.cdc.gov/vaccinesafety/Activities/vaers. html. Accessed December 10, 2012.
23. Date AA, Kyaw MH, Rue AM, et al. Long-term persistence of mumps antibody after receipt of 2 measles-mumps-rubella (MMR) vaccinations and antibody response after a third MMR vaccination among a university population. J Infect Dis. 2008;197:1662-1668.
24. CDC. Update: Mumps outbreak-New York and New Jersey, June 2009-January 2010. MMWR Morb Mortal Wkly Rep. 2010;59:125-129.
25. Anis E, Grotto I, Moerman L, et al. Mumps outbreak in Israel's highly vaccinated society: are two doses enough? Epidemiol Infect. 2012;140:439-446.
26. Whelan J, van Binnendijk R, Greenland K, et al. Ongoing mumps outbreak in a Studentpopulation with high vaccination coverage, Netherlands, 2010. Euro Surveill. 2010;15(17):pii=l 9554. Available at: http://www.eurosurveillance.org/ ViewArticle.aspx?ArticleId=19554. Accessed December 10, 2012.
27. Bangor-Jones RD, Dowse GK, Giele CM, et al. A prolonged mumps outbreak among highly vaccinated Aboriginal people in the Kimberley region of Western Australia. Med J Aust. 2009;191:398-401.
28. Yeung LF, Lurie P, Dayan G, et al. A limited measles outbreak in a highly vaccinated US boarding school. Pediatrics. 2005;116:1287-1291.
29. Laurence D, McGavin D The complications of mumps. Br Med J. 1948;1:94-97.
30. Association for the Study of Infectious Disease. A retrospective survey of the complications of mumps. J R Coll Gen Pract. 1974;24:552-556.
31. Beard CM, Benson RC Jr, Kelalis PP, et al. The incidence and outcome of mumps orchitis in Rochester, Minnesota, 1935 to 1974. Mayo Clin Proc. 1977;52:3-7.
32. Arday DR, Kanjarpane DD, Kelley PW Mumps in the US Army 1980-86: should recruits be immunized? Am J Public Health. 1989;79:471-474.
33. Connolly NK. Mumps orchitis without parotitis in infants. Lancet. 1953;1:69-70.
34. Atkinson JE, Bass HN. Mumps orchitis in a 3-year-old child. JAMA. 1968;203:892.
35. Parker Fiebelkorn A, Barskey AE, Hickman C, Bellini W Mumps. In: Centers for Disease Control and Prevention, ed. Manual for the Surveillance of Vaccine-Preventable Diseases 2012. Available at: http://www.cdc.gov/vaccines/ pubs/surv-manual/chpt09-mumps.html. Accessed December 10, 2012.
36. WHO. WHO/IVB database. 2011 [updated Jul 20,2012]. Available at: http://www.who.int/immunization-monitoring/diseases/Mumps-map-schedule. jpg. Accessed December 10,2012.
37. U.S. Department of Transportation. Research and Innovative Technology Administration Bureau of Transportation Statistics. T-100 international segment (all carriers). 2011 [updated Mar 21, 2012]. Available at: http://transtats.bts. gov/DL-SelectFields.asp?Table-ID=261. Accessed December 10,2012.
38. CDC. Notice to Readers: Updated Recommendations of the Advisory Committee on Immunization Practices (ACIP) for the Control and Elimination of Mumps. MMWR Morb Mortal Wkly Rep. 2006;55:629-630.
39. Cohen C, White JM, Savage EJ, et al. Vaccine effectiveness estimates, 2004-2005 mumps outbreak, England. Emerging Infect Dis. 2007;13:12-17.
40. Deeks SL, Lim GH, Simpson MA, et al. An assessment of mumps vaccine effectiveness by dose during an outbreak in Canada. CMAJ. 2011;183:1014-1020.
41. Snijders BE, van Lier A, van de Kassteele J, et al. Mumps vaccine effectiveness in primary schools and households, the Netherlands, 2008. Vaccine. 2012;30:2999-3002.
42. McLean H. Summary and discussion: third dose of MMR vaccine for mumps control. Presented at: Meeting of the Advisory Committee on Immunization Practices; February 22-23, 2012; Atlanta, GA. Available at: http://www.cdc.gov/ vaccines/acip/meetings/downloads/slides-feb-2012/06-MMR-McLean.pdf. Accessed December 10, 2012.
43. Mahamud A, Parker Fiebelkorn A, Nelson G, et al. Economic impact of the 2009-2010 Guam mumps outbreak on the public health sector and affected families. Vaccine. 2012;30:6444-6448.